Market Overview

United Therapeutic Shares Rocketing Higher Following FDA Approval of Orenitram, JP Morgan Upgrade

Share:
Related UTHR
The Daily Biotech Pulse: KemPharm, FDA Nod For Merck, Clovis Q3 Miss, 3 Stocks To Debut
Earnings Scheduled For October 31, 2018

Shares of United Therapeutic (NASDAQ: UTHR) are up more than 23 percent just after Monday morning's opening bell, breaking to a new high over $108.

United Therapeutic announced on Friday that the United States Food and Drug Administration approved Orenitram (treprostinil) Extended-Release Tablets for the treatment of pulmonary arterial hypertension (PAH) in WHO Group I patients to improve exercise capacity. United Therapeutics' President and Chief Operating Officer commented that this approval supports the company's mission to provide a "wider choice of PAH therapies for physicians and patients."

Monday morning JP Morgan analyst Geoffrey Meacham upgraded the stock form Underweight to Neutral and raised the price target from $62.00 to $90.00.

Despite the optimism in share price, Meacham noted that approval isn't enough to warrant a move to Overweight. The analyst cited the Sandoz litigation on Remodulin, a potential competition in PAH from Actelion's selexipag. In addition, JP Morgan commented that the Orenitram label appears "very restrictive."

United Therapeutic closed at a record high on December 2, at $94.95. Shares closed at $87.84 on Friday. Shares of United Therapeutic are currently up 23.06% at $108.10.

Latest Ratings for UTHR

DateFirmActionFromTo
Nov 2018Credit SuisseMaintainsUnderperformUnderperform
Nov 2018JP MorganMaintainsNeutralNeutral
Nov 2018Credit SuisseMaintainsUnderperformUnderperform

View More Analyst Ratings for UTHR
View the Latest Analyst Ratings

Posted-In: Analyst Color News Upgrades FDA Analyst Ratings

 

Related Articles (UTHR)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
DLTRBernsteinUpgrades0.0
CNPUBSUpgrades34.0
UGIUBSDowngrades63.0
ATOUBSDowngrades106.0
CSCONomuraDowngrades50.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Signs Pointing Toward Another Santa Claus Rally In 2013

Baird Upgrades Fortinet on New CFO Appointment and Revenue Catalysts